Palliative chemotherapy for advanced NSCLC

被引：0

作者：

Schütte W. ^{[1
]}

机构：

[1] Klinik für Innere Medizin, Städtisches Krankenhaus Martha-Maria Halle-Dölau, 06120 Halle

来源：

Der Pneumologe | 2005年 / 2卷 / 4期

关键词：

Chemotherapy; Lung cancer; Non-small cell; Prognosis; Treatment;

D O I：

10.1007/s10405-005-0048-x

中图分类号：

学科分类号：

摘要：

Palliative chemotherapy is the standard of care for patients in good general condition with advanced NSCLC. Double combination of cisplatin or carboplatin with one of the new substances such as docetaxel, gemcitabine, paclitaxel, or vinorelbine is indicated for first-line treatment. Monotherapy with one of the new substances is associated with decreased effect but can represent an advisable alternative for older patients with comorbidities. A triple combination does not prolong life but instead increases toxicity. The duration of therapy should be four to a maximum of six cycles. Prognostic parameters for the efficacy of chemotherapy are general condition, serum LDH level, and extent of weight loss. For patients in good general condition with ECOG 0-2, second-line chemotherapy with docetaxel administered every 3 weeks is standard. Alternatives are docetaxel or pemetrexed given weekly. These treatment regimens offer patients the possibility for prolonged life and improved symptomatology and quality of life. © Springer Medizin Verlag 2005.

引用

页码：260 / 267

页数：7

共 30 条

[1]

Belani C.P., Barstis J., Perry M.C., Et al., Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation, J. Clin. Oncol., 21, pp. 2933-2939, (2003)

[2]

Bernhard J., Maibach R., Thurlimann B., Et al., Patients' estimation of overall treatment burden: Why not ask the obvious?, J. Clin. Oncol., 20, pp. 65-72, (2002)

[3]

Bonomi P., Kim K., Fairclough D., Et al., Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial, J. Clin. Oncol., 18, pp. 623-631, (2000)

[4]

Borges M., Sculier J.P., Paesmans M., Et al., Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC), Lung Cancer, 16, pp. 21-33, (1996)

[5]

Depierre A., Quoxi E., Mercier M., Et al., Chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized study of Vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction therapy, Proc. Am. Soc. Clin. Oncol. 2001, (2001)

[6]

Font A., Sanchez J.M., Taron M., Et al., Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism, Invest. New Drugs, 21, pp. 435-543, (2003)

[7]

Fossella F.V., DeVore R., Kerr R.N., Et al., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, J. Clin. Oncol., 18, pp. 2354-2362, (2000)

[8]

Fossella F., Pereira J.R., Pluzanska A., Et al., Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group, J. Clin. Oncol., 21, pp. 3016-3024, (2003)

[9]

Georgoulias V., Ardavanis A., Tsiafaki X., Et al., Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial, J. Clin. Oncol., 23, (2005)

[10]

Gridelli C., Gallo C., Shepherd F.A., Et al., Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol., 21, pp. 3025-3034, (2003)

← 1 2 3 →